Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 16/20 | 0.72 |
| ▸ | NPC1 | O15118 | 15/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244264 | 0.96 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL3241511 | 0.89 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL3245157 | 0.86 | ALDH1A1 (0.60) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3241519 | 0.83 | ALDH1A1 (0.58) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL13293301 | 0.81 | NPC1 (0.80) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL3245109 | 0.81 | ALDH1A1 (0.60) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL13293346 | 0.80 | ALDH1A1 (0.54) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL27179885 | 0.80 | ALDH1A1 (0.66) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL13293310 | 0.79 | RAB9A (0.80) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL13293317 | 0.78 | ALDH1A1 (0.57) | RAB9ANPC1SMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745490-B2 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTEOTECH, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745490-B2 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTEOTECH, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1751097-B1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1751097-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2005113489-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | RAB9A 2958/4885NPC1 1032/4885SMN1; SMN2 24/4885 |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | IAPP, SNCA, BACE2 | RAB9A 2893/4885NPC1 1016/4885SMN1; SMN2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.